How dissolved polymers change ibuprofen's amorphous solubility and the fate of its drug-rich droplets

Background and motivation

An amorphous solid dispersion (ASD) can dissolve to concentrations far above the crystalline solubility of a poorly water-soluble drug. When the dissolved concentration exceeds the drug's amorphous solubility, the drug can no longer stay in water as a single phase, and the excess separates as a colloidal drug-rich phase by liquid–liquid phase separation (LLPS), or glass–liquid phase separation when the separated phase is glassy (Ilevbare 2013, ref 16; Mosquera-Giraldo 2015, ref 17; Almeida e Sousa 2015, ref 18). C1 This drug-rich phase is itself poorly permeable, but it can act as a reservoir: it keeps the bulk solution at its maximum concentration while drug is absorbed across a membrane (Indulkar 2016, ref 19). C2 The droplets are thermodynamically unstable, however. They can crystallize, or coarsen and then cream or sediment (Lindfors 2006, ref 20; Ilevbare 2013, ref 21). C2

Polymers are known to act on this phase. Hypromellose (HPMC) improves the size stability of drug-rich droplets and suppresses crystallization (refs 21, 22). For nifedipine with HPMC derivatives, polymer mixing into the drug-rich phase and the resulting slower drug motion are "thought to contribute" to crystallization inhibition (Ueda 2017, ref 23), and polymer adsorption at the amorphous surface–water interface has also been suggested to matter (refs 21, 24). C3 The authors state that it was still unclear how a polymer affects the dispersion stability of the drug-rich phase. C3

There is also a thermodynamic cost. When a polymer mixes substantially into the drug-rich phase, it dilutes the drug there, lowers the drug's chemical potential, and so lowers the amorphous solubility; the maximum achievable supersaturation, and with it the membrane transport rate, then fall (Ueda 2019, ref 22; Mosquera-Giraldo 2018, ref 31; Trasi 2015, ref 35). C4·C6 The opposite case is solubilization: an additive that binds or micellizes dissolved drug raises the apparent amorphous solubility, but that extra dissolved drug does not raise membrane transport (Lu 2017, ref 32; Indulkar 2017, ref 33). C5 Solution NMR can tell these cases apart, because solubilization changes the chemical environment of dissolved drug (refs 10, 34). C5 To predict the properties of the drug-rich phase, the authors argue, one must also look at the drug inside that phase. C6

That is usually impossible by solution NMR. For drugs with a higher glass transition temperature (Tg), such as nifedipine (Tg 42 °C) and glibenclamide (Tg 59 °C), only dissolved drug is detected; drug inside the viscous amorphous nanoparticles tumbles too slowly to give a solution spectrum (refs 23, 36). R16·C7 Ibuprofen (IBP) is different: with a Tg of −45 °C, its drug-rich phase is a mobile liquid at 37 °C, and an earlier study by Ueda and co-workers showed that IBP can be observed both dissolved and inside the IBP-rich phase (Ueda 2019, ref 22). M1·C7

The paper uses this to compare three chemically different polymers widely used in ASDs: HPMC, polyvinylpyrrolidone/vinyl acetate (PVP-VA, Kollidon VA 64) and the amino methacrylate copolymer Eudragit E PO (EUD-E). It asks how each polymer changes the amorphous solubility of IBP and the size and dispersion stability of the IBP-rich colloidal phase, and it uses ¹H NMR to locate drug and polymer, and dynamic light scattering (DLS) to follow droplet size over time. A1·P4·P6

Background concepts

Amorphous and crystalline solubility. The crystalline solubility (here S_c,IBP) is the equilibrium concentration over the crystal. The amorphous solubility (S_a,IBP) is the concentration at which a drug-rich liquid phase separates; it is the highest concentration a supersaturated solution can reach as a single phase. Their ratio, S_a,IBP/S_c,IBP, is the maximum supersaturation, which the paper calls the concentration-based supersaturation ratio. R1·C10 The paper measures S_a,IBP by the UV-extinction method: a concentrated drug solution is added slowly to the medium, and the concentration at which light at 400 nm starts to be scattered marks the onset of LLPS. P3

Two ways an additive moves the amorphous solubility. An additive that enters the drug-rich phase lowers the drug's activity there, so less drug is needed in water to coexist with it: the amorphous solubility falls. C6 An additive that binds dissolved drug in water lowers the activity of the dissolved drug, so more total drug can dissolve before phase separation: the apparent amorphous solubility rises. C9 The two mechanisms leave different fingerprints in NMR: the first changes the spectrum of drug inside the droplets, the second the spectrum of dissolved drug. C5·C6

What solution NMR sees. Above the amorphous solubility, IBP gives two sets of peaks: one from dissolved IBP and one, at higher field (lower ppm), from IBP inside the IBP-rich droplets; the droplet-phase peaks report the average state of IBP in that phase. R9·C19 A peak's position (chemical shift) reflects the chemical environment of the proton; a peak's width reflects molecular mobility, and broadening means slower motion (refs 41, 42). C21 A molecule that tumbles very slowly, such as a polymer chain caught in a viscous phase, disappears from a solution spectrum altogether; this is what the paper uses to follow where the polymer goes. C22 Dissolved IBP that exchanges quickly with a slow droplet phase can also be broadened, by what the authors call the lifetime broadening effect (ref 22). C24

The droplets as an emulsion. Because IBP's Tg is below the experimental temperature, the drug-rich phase is a supercooled liquid, and the authors treat the dispersion as an emulsion. C38 An emulsion coarsens by three processes (refs 40, 49, 50). C39 In Ostwald ripening, dissolved drug diffuses through the water from small droplets to large ones. In flocculation, droplets stick together, reversibly or not; in coalescence, they merge, often after flocculating. Large droplets then cream (rise) or sediment. DLS cannot easily tell flocculation from coalescence, because both bring particles together. C39 The rate of Ostwald ripening is given by the Lifshitz–Slyozov–Wagner expression the paper prints as Equation 1 (refs 51, 52):

Here $⟨d⟩$ is the mean droplet diameter, $t$ time, $\gamma$ the interfacial tension between droplet and water, $V_m$ the molar volume, $C_{\infty }$ the solubility of the drug in the bulk water, $D$ the diffusivity of the dissolved drug, $\rho$ the density of the dispersed phase, $R$ the gas constant and $T$ the temperature. E1 In plain terms: the cube of the mean diameter grows at a constant rate that is proportional to how much drug the water dissolves and to the interfacial tension. A droplet phase whose drug is very soluble in the surrounding water ripens fast; anything that lowers the solubility or the interfacial tension slows ripening. E1·C41 The paper uses only these proportionalities, not absolute rates; the AI writer notes that the prefactor 8/9 is the one usually written for the cube of the mean radius, so the printed form should not be used for absolute rates. X14

Zeta potential. The zeta potential is the electrical potential of the layer that moves with a droplet; a large value of either sign means strong charge repulsion between droplets. In the paper it serves as evidence that the cationic polymer EUD-E is adsorbed on the droplets. R6·C16

Methods in detail

The design is deliberately narrow: one drug, three polymers each at 300 µg/mL, one medium. All experiments used 50 mM phosphate buffer at pH 2.0 prepared in deuterium oxide (D₂O), at 37 °C, and the polymer-free buffer served as the control. P1·M7·A1 The paper makes three contributions, which the method flow below summarizes. A1·A2·A3

Contribution 1: Measuring both solubilities in each polymer solution

Problem. To know whether a polymer changes the maximum supersaturation, both the crystalline and the amorphous solubility must be measured in the presence of the dissolved polymer, not only in buffer. C4·C10

What they did. For S_c,IBP, excess crystalline IBP was stirred for 48 h at 37 °C in buffer or polymer solution, centrifuged at 14800 rpm (21100 ×g) for 20 min, and the supernatant diluted with acetonitrile and assayed by HPLC (C18 column, 70% acetonitrile/30% pH 2.0 phosphate buffer, 1 mL/min, UV 260 nm), n = 3. P2 For S_a,IBP, a 25 mg/mL methanolic IBP stock was added by syringe pump at 20 µL/min to 15 mL of medium at 37 °C, and the concentration at which scattering at 400 nm appeared was taken as the amorphous solubility, n = 3 (method of Ilevbare and Taylor, ref 16). P3 In the Supporting Information the same measurement was repeated at 0, 150, 300 and 500 µg/mL HPMC and PVP-VA (Figure S2). P1·R2

Why it works. The ratio S_a,IBP/S_c,IBP separates the two mechanisms of the background section: a solubilizer raises both solubilities, whereas a polymer that dilutes the drug-rich phase lowers only the amorphous one. C9·C10·C32

Contribution 2: Locating drug and polymer by solution ¹H NMR

Problem. The solubility numbers alone do not say where a polymer acts. The paper uses IBP's visibility in both phases to find out. C7

What they did. An IBP stock in methanol-d4 was added to buffer or polymer solution (2% v/v final methanol-d4) at 37 °C, and ¹H spectra were recorded at 37 °C on an 800 MHz spectrometer with a cryoprobe, using trimethylsilyl propionate (TSP) as internal reference for chemical shift and for quantification, and a 12~15 s repetition delay (five times the spin-lattice relaxation time T₁). P4 The IBP peaks were decomposed by Lorentzian curve fitting into a dissolved set and a droplet-phase set, and the concentrations of IBP in each phase, and of dissolved polymer, were calculated from the peak areas against TSP. P4 Two IBP levels were used: half of S_a,IBP in each medium, where no droplets exist (Figure 2), and S_a,IBP + 100, + 200 and + 300 µg/mL, where droplets form (Figures 5–7). P4·A2 Because each concentration is set relative to the S_a,IBP of its own medium, the amount of droplet phase is roughly comparable across media, although the total IBP differs. A2·R1.b

Why it works. Below S_a,IBP, any change in the IBP or polymer peaks must come from interactions in solution. R3·R4 Above S_a,IBP, broadening or shifting of the droplet-phase peaks reports a changed environment inside the droplets, and loss of polymer signal reports polymer that has become too slow to be seen, which the authors take as polymer that has entered the IBP-rich phase. C21·C22

Contribution 3: Following droplet size, charge and stability

Problem. The practical question is how large the droplets are and whether they stay dispersed. A1·A3

What they did. Droplets were made by adding a methanolic IBP stock (2% v/v final methanol) to buffer or polymer solution at 37 °C and measured fresh by DLS (Malvern Nano-ZS, backscatter detection at 173°, 37 °C) for average diameter and polydispersity index (PDI) at the three supersaturations (Table 2), and for zeta potential at S_a,IBP + 300 µg/mL (Figure 3), n = 3. P6 Dispersions at S_a,IBP + 300 µg/mL were then stirred at 300 rpm and 37 °C; DLS size and derived count rate (Figure 4), the NMR spectra (Figure 8) and the NMR-derived IBP concentrations in each phase (Figure 9) were recorded after 0.5, 1, 2 and 3 h, and the vials were photographed at the start and after 3 h (Figure S1). P5·P7·P8 The figures also show a first point at 0–5 min that the methods do not describe; it is best read as the freshly prepared dispersion. X7 The buffer dispersion was also stirred for 24 h to check for crystals. P8

How it differs from earlier work. Earlier studies from the same groups had shown, for one polymer (HPMC), that the polymer enters IBP-rich droplets and slows IBP motion (ref 22). C3·C21 This paper compares three polymers of different chemistry and charge side by side and adds droplet size, charge and stability under stirring to the NMR picture. A1

Experimental analysis

The amorphous solubility: halved by HPMC and PVP-VA, raised by EUD-E

Table 1 gives the central thermodynamic result (Table A below). In buffer, S_c,IBP was 29.8 µg/mL and S_a,IBP 177.1 µg/mL, a supersaturation ratio of 5.94. R1 HPMC and PVP-VA left the crystalline solubility unchanged (30.0 and 30.1 µg/mL) but lowered the amorphous solubility to 96.9 and 90.7 µg/mL, so the maximum supersaturation fell to 3.23 and 3.01. R1·C8·C10 EUD-E raised both: S_c,IBP to 42.1 and S_a,IBP to 256.3 µg/mL, leaving the ratio at 6.09, similar to buffer. R1·C8·C10 The authors attribute the EUD-E increase to solubilization, citing that EUD-E solubilizes anionic drugs at 0.1–5% (w/w) (Saal 2017, ref 37) and that solubilization lowers the activity of the dissolved drug. C9·R19

Table A. Crystalline and amorphous solubility of IBP at 37 °C, pH 2.0 phosphate buffer in D₂O; SD in parentheses, n = 3 (from Table 1). R1

Figure S2 shows how the amorphous solubility depends on polymer concentration. Most of the drop happens by 150 µg/mL (from about 177 to about 111 µg/mL with HPMC and about 101 µg/mL with PVP-VA); between 300 and 500 µg/mL the values change little (about 97 to 93 and 91 to 89 µg/mL). R2 The authors cite the figure for the statement that the bulk drug concentration "reduces further as more polymer is added"; the AI writer notes that the curve levels off above about 300 µg/mL in this system. C37·X5

Where the polymers go: HPMC and PVP-VA into the droplets, EUD-E into complexes in water

Below the amorphous solubility (Figure 2). With IBP at half of S_a,IBP, HPMC and PVP-VA changed neither the position nor the shape of the IBP peaks, and IBP did not change the polymer peaks: these two polymers do not interact noticeably with dissolved IBP. R3·C11 With EUD-E the IBP peaks shifted (for example one aromatic peak from about 7.24 to about 7.21 ppm), and the EUD-E peaks changed shape and position when IBP was present. R4 The authors read this as "consistent with" an EUD-E–IBP interaction in water that solubilizes IBP, as earlier reported for mefenamic acid with EUD-E through hydrogen bonding and hydrophobic interaction (Higashi 2014, ref 38; Kojima 2012, ref 39). C12

Above the amorphous solubility (Figures 5–7). In buffer, the aromatic protons of IBP give a dissolved pair at about 7.29 and 7.25 ppm and a droplet-phase pair at higher field, about 6.96 and 6.78 ppm (Figure 5). R9 As IBP was raised from S_a,IBP + 100 to + 300 µg/mL, the droplet-phase peaks grew, the dissolved peaks stayed constant, and the droplet-phase peaks moved slightly up-field (to about 6.95 and 6.77 ppm). R9 The authors explain this shift by droplet size: IBP near the droplet surface sits in a more polar environment than IBP in the core, and larger droplets have a smaller surface fraction (the shift "is due to" a less polar average environment). C20

With HPMC and PVP-VA the droplet-phase peaks were broad and lay down-field of buffer, at about 7.06–7.04 and 6.87–6.85 ppm with HPMC and about 7.10–7.09 and 6.91–6.90 ppm with PVP-VA (Table B). R10 The authors read the broadening as strongly suppressed IBP mobility in the droplets, and the shift as a changed chemical environment, "consistent with" their earlier finding that HPMC distributes into the IBP-rich phase (ref 22). C21 At the same time, the polymer peaks kept their shape and position but lost intensity as more droplet phase formed (Figure 6). R12 Quantified against TSP (Figure 7), dissolved HPMC fell from the 300 µg/mL dose to about 214, 174 and 141 µg/mL, and dissolved PVP-VA to about 215, 148 and 85 µg/mL, at S_a,IBP + 100, + 200 and + 300 µg/mL. R13 The authors conclude that "it is apparent that HPMC and PVP-VA distributed into the IBP-rich phase", where the slow tumbling of the mixed polymer removes it from the solution spectrum. C22·C23

A third observation supports this picture. Above S_a,IBP, the dissolved-IBP peaks were also broader in HPMC and PVP-VA than in buffer, although the same polymers had left them sharp below S_a,IBP. R10·R3 Because the solution viscosity is the same in both cases, the authors attribute the broadening to exchange of dissolved IBP with the slow, polymer-loaded droplet phase. C24 During stirring in PVP-VA, as the droplet-phase peaks shrank, the dissolved-IBP peaks became narrower again and showed resolved splitting at 2 and 3 h; in HPMC, where the droplets stayed, they stayed broad (Figure 8). R14 Note by the AI writer (not discussed in the paper): this recovery as the droplets leave fits the exchange explanation. R14·C24

EUD-E behaved differently in every respect. Its droplet-phase IBP peaks stayed near their buffer positions (about 6.97–6.95 and 6.80–6.78 ppm) and much sharper than with HPMC or PVP-VA; its own signal stayed at about 296–289 µg/mL; and its dissolved-IBP peaks moved up-field, to about 7.24 and 7.13 ppm. R11·R13 The authors conclude that most EUD-E stayed in the water and did not enter the droplets, and that complexes between IBP and EUD-E in water caused the shift of the dissolved-IBP peaks. C25·C26

Table B. NMR fingerprints of polymer location; peak ranges run from S_a,IBP + 100 to + 300 µg/mL; polymer dose 300 µg/mL (read from Figures 5 and 7, approximate). R9·R10·R11·R13

Note by the AI writer (not discussed in the paper). Loss of solution-NMR signal shows that the polymer has become immobile, not where it sits: polymer adsorbed at the droplet surface would also vanish from the spectrum. The broadened, shifted droplet-phase IBP peaks argue for polymer inside the droplets, but the droplet composition was not measured. If all the missing polymer at S_a,IBP + 300 µg/mL (about 159 µg/mL HPMC, about 215 µg/mL PVP-VA) were inside the droplets, which hold about 260–300 µg/mL IBP, polymer would make up roughly 35–45% of the water-free droplet mass. X4

Fresh droplets: small with HPMC and PVP-VA, large with EUD-E, micrometre-sized without polymer

Without polymer, the IBP-rich phase coarsened rapidly: DLS gave 3182–5313 nm with PDI 1.00 at all three supersaturations (Table 2). R5·C13 The AI writer notes that a PDI of 1.00 is the top of the scale, so these numbers say only that the droplets were micrometre-sized. X10 With any polymer, nano-sized droplets formed. With HPMC they measured 272, 330 and 345 nm at S_a,IBP + 100, + 200 and + 300 µg/mL, all at PDI 0.04; with PVP-VA, 268, 296 and 320 nm at PDI 0.07, 0.22 and 0.21; with EUD-E, 472, 709 and 808 nm at PDI 0.43–0.55 (Table C). R5 The authors call the PVP-VA PDIs "slightly greater" than those with HPMC; at the two higher concentrations they are about five times larger. C15·X9 They read the larger size and broad PDI with EUD-E as a weak inhibition of early coarsening ("it appears"), and the rise in EUD-E droplet size with IBP concentration as consistent with emulsions destabilizing at higher oil content (Gupta 2016, ref 40). C14·C15

Zeta potential separated EUD-E from the rest (Figure 3): −1.92 mV in buffer, 0.12 mV with HPMC, 1.45 mV with PVP-VA, and 64.85 mV with EUD-E. R6 EUD-E is positively charged at pH 2.0, and the authors take the large positive value as "consistent with" EUD-E adsorbed on the droplets. C16·M4

Table C. Average diameter (nm) and PDI (in parentheses) of freshly prepared IBP-rich droplets at 37 °C, n = 3 (from Table 2; SDs omitted), and zeta potential (bar labels of Figure 3). R5·R6

Under stirring: HPMC and EUD-E keep the droplets, PVP-VA and buffer lose them

The stability test used S_a,IBP + 300 µg/mL dispersions stirred at 300 rpm and 37 °C for 3 h (Table D). P5·P7 By NMR (Figure 9), the dissolved IBP stayed constant in every medium. R15·C28 The droplet-phase IBP did not: in buffer it fell from about 300 µg/mL at the first point to about 52 µg/mL at 30 min and about 5 µg/mL at 1 h, and the droplet peaks were absent from the 1 h spectrum on (Figure 8). R15·R14 With PVP-VA it fell steadily, from about 264 to about 120 µg/mL at 2 h and about 67 µg/mL at 3 h. R15 With HPMC and EUD-E it fell only to about 183 and 173 µg/mL, from about 260 and 249 µg/mL. R15 The authors describe this as creaming that was rapid without polymer, "delayed" with HPMC and EUD-E, and slowed but not prevented with PVP-VA. C27·C28

DLS tells the same story in a different way (Figure 4). R7 Without polymer, the droplets fell below the DLS detection limit by 30 min. R7·C17 With HPMC, droplet size stayed at about 345–385 nm and the derived count rate at about 275–320 × 10⁶ cps. R7 With PVP-VA the size of the remaining droplets stayed at about 320–440 nm, but the count rate dropped from about 470 to about 95 × 10⁶ cps at 1 h and about 35 × 10⁶ cps at 3 h. R7 With EUD-E the droplets grew from about 810 to about 1110 nm while the count rate fell from about 200 to about 120 × 10⁶ cps. R7·C18 The photographs (Figure S1) match: after 3 h the polymer-free vial was clear, with a large IBP-rich droplet floating on the surface, the PVP-VA vial was less turbid, and the HPMC and EUD-E vials looked unchanged. R8 No crystals appeared in buffer within 3 h, but IBP crystallized within 24 h of stirring (data not shown). R8·C17

Table D. Stability of S_a,IBP + 300 µg/mL dispersions under stirring at 300 rpm, 37 °C (read from Figures 9 and 4, approximate; appearance from Figure S1). R15·R7·R8

From these data the authors conclude that HPMC "effectively improved" dispersion stability and that PVP-VA "is less effective at preventing flocculation and creaming than the other polymers". C18·C29 The AI writer notes two limits of that ranking. By NMR, HPMC and EUD-E each lost about 30% of the droplet-phase drug over 3 h, so HPMC's lead over EUD-E rests on droplet size and count rate, not on retained droplet phase. X12 And flocculation was not measured as such: in PVP-VA the mean size of the droplets that remained barely changed while the count rate collapsed, so the step between small droplets and creamed material was not observed. X11

Note by the AI writer (not discussed in the paper). The NMR-detected dissolved IBP during stirring (about 168 µg/mL in buffer, 117–121 with HPMC, 90–97 with PVP-VA and 273–278 with EUD-E) is not identical to the UV-extinction S_a,IBP of Table 1; it is about 20 µg/mL higher with HPMC and EUD-E and about 9 µg/mL lower in buffer. The two methods are not compared in the paper, so the Table 1 values should be used as the amorphous solubilities. X1·R15·R1

Discussion

The authors' mechanism

The discussion joins the results into one chain, shown below. Each step is the authors' interpretation; the hedges they use are given in the text. C32·C47·C49·C50·C51

Solubility. The authors state that a large amount of HPMC and PVP-VA distributed into the IBP-rich droplets, "leading to a significant reduction" of S_a,IBP, and that this arises from dilution of the drug, which lowers its chemical potential. C32·C33 They call the observation "potentially important", because both are common ASD polymers that "appear" to diminish the maximum achievable supersaturation of IBP. C33 For EUD-E, the high hydrophilicity that comes from ionized amino methacrylate groups "explains" its low tendency to mix with the drug-rich phase, so it does not lower the chemical potential of IBP there; it instead raises both solubilities by complexation. C34·C35 Since the supersaturation ratio is unchanged with EUD-E, the free drug and the complex "may remain constant" in proportion between S_c,IBP and S_a,IBP, in which case complexation would cost no supersaturation advantage; the authors add that this "would need to be confirmed". C36

Initial droplet size. The authors first note that the PDI could not reveal the route of instability, because the droplets creamed, and that their molecular data can only be used to "speculate". C40 By Equation 1 the ripening rate scales with the bulk solubility, so a twofold lower S_a,IBP (177.1 to 96.9 or 90.7 µg/mL; ratios 1.83 and 1.95) would slow ripening only about twofold, yet the polymers "appear" to slow it more. C42·E1·R1 They therefore consider further brakes. The classic way to stop ripening, an oil-miscible additive with extremely low water solubility that concentrates in shrinking droplets (Wooster 2008, ref 53), "cannot be directly invoked" for water-soluble polymers. C43 Instead, because polymers diffuse about 10 times slower than drug (refs 34, 54), a temporary polymer excess in small droplets "could be envisaged", and polymer in or on the droplets "would reduce" the interfacial tension. C44·C45·R17 Since early nanoemulsion growth is "generally thought" to occur by Ostwald ripening (Gupta 2016, ref 40), the smaller fresh droplets with HPMC and PVP-VA "may reflect" inhibition of early ripening by polymer mixing. C46·C47 For EUD-E, the small amount of mixed polymer and the higher S_a,IBP "most likely account for" the larger fresh droplets, as solubilization of the oil by a surfactant is known to speed ripening (ref 57). C48

Long-term stability. Despite its large fresh droplets, EUD-E improved dispersion stability relative to buffer and PVP-VA. The authors attribute this to adsorbed cationic EUD-E, which "would lead to charge repulsion between approaching droplets", lowering the chance of flocculation and coalescence (Mason 2006, ref 58). C49 PVP-VA "proved to be ineffective" at preventing coarsening and creaming even though it suppressed initial ripening: it is uncharged, and "Clearly, PVP-VA also does not provide sufficient steric repulsion". C50 HPMC is reported to stabilize emulsions sterically when adsorbed at the oil–water interface (Schulz 2000, ref 59; Wollenweber 2000, ref 60), and the authors conclude that HPMC is "the most effective polymer" because it combines ripening inhibition by mixing with coalescence inhibition by steric repulsion. C51

The trade-off and what it means for formulation

The authors frame polymer mixing as a trade-off: it "provides inter-related benefits and disadvantages", namely better size stability and, from earlier work, a lower tendency to crystallize, against a lower maximum supersaturation. C52 Because a high polymer loading is chosen to inhibit crystallization, and the bulk drug concentration falls with polymer concentration (Figure S2), they suggest that a higher polymer:drug ratio "can conceivably" reduce the supersaturation advantage further and that the polymer should be evaluated case by case. C37 More generally, the effect of the polymer, or of additives such as surfactants, on droplet size and stability, crystallization tendency and amorphous solubility "needs to be investigated and balanced against the likely in vivo impacts": smaller droplets "appear to provide an absorption advantage" (Kesisoglou 2019, ref 28), while a lower amorphous solubility "is expected to decrease" membrane transport. C53 They also argue that droplets able to diffuse into the unstirred water layer next to the intestinal wall "could improve" transport to the epithelium, given a mucin mesh with pores of about 10–200 nm (Yildiz 2015, ref 46). C30·C31·R18

Note by the AI writer (not discussed in the paper). Three practical points follow from the data, with the limits below. First, an amorphous solubility measured in plain buffer can overstate what a formulation reaches once its polymer is dissolved: for IBP, 300 µg/mL HPMC or PVP-VA roughly halved it, and most of the drop was already reached at 150 µg/mL. R1·R2 Second, small fresh droplets are not enough: PVP-VA gave droplets as small as HPMC but lost most of the droplet-phase drug within 3 h of stirring. R5·R15 Third, a solubilizing polymer that raises both solubilities equally, as EUD-E did, adds dissolved drug but not supersaturation, and its charge stabilization belongs to the acidic pH at which it is ionized. R1·X6

Limitations

Limits the authors state

The authors state that PDI measurements "did not provide useful mechanistic insights" because the droplets creamed, so the routes of droplet growth are "speculate[d]" from the molecular data. C40 They mark the EUD-E supersaturation argument as needing confirmation ("would need to be confirmed by additional studies"). C36 They also hedge most mechanistic steps: "may reflect", "could be envisaged", "would reduce", "most likely account for". C44·C45·C47·C48

The AI writer's own judgement

Overall, moderate. The solubility data and the NMR evidence on where each polymer goes are direct, quantitative and mutually consistent; the explanations for droplet size and stability rest mainly on interpretation and cited emulsion work. R1·R13·X2·X3

• Ostwald ripening was not measured. The ripening account rests on fresh droplet sizes, whose age is not stated, and on Equation 1; it is hedged in the discussion ("may reflect") but stated as fact in the conclusion ("contributed"). X2·X7
• Steric stabilization by HPMC is cited, not shown. The zeta potential with HPMC (0.12 mV) is close to buffer, and no adsorption or interfacial-tension measurement was made. X3·R6
• Polymer location and droplet composition are open. NMR signal loss does not distinguish polymer inside the droplets from polymer adsorbed on them. X4
• The stability ranking is partly qualitative. Flocculation was not measured separately, and by NMR HPMC and EUD-E retained a similar share of droplet-phase drug. X11·X12
• Measurement details. The buffer droplet sizes sit at the PDI ceiling; NMR and UV-extinction values for dissolved IBP differ by up to about 20 µg/mL; the PVP-VA PDIs are about five times those of HPMC, not "slightly" larger. X10·X1·X9
• Scope. One drug, pH 2.0 phosphate buffer in D₂O with 2% (v/v) methanol, one polymer concentration for most tests, dissolved polymers rather than dissolving ASDs, and no membrane-transport or crystallization measurements beyond a 24 h check in buffer. The EUD-E charge and solubilization results belong to this pH. X6·R8
• Minor source issues. The Figure 5 caption describes brown dashed lines that are red in the figure; the abstract's "around 800 nm" for EUD-E is the S_a,IBP + 300 µg/mL value, the smallest being 472 nm. X13·X8

Conclusion

The paper shows, for ibuprofen at pH 2.0, that three common ASD polymers act on the drug-rich phase in two distinct ways. HPMC and PVP-VA enter the IBP-rich droplets: the amorphous solubility falls from 177.1 to 96.9 and 90.7 µg/mL, the droplet-phase drug becomes less mobile, and fresh droplets stay at about 270–345 nm. R1·R10·R13·R5 EUD-E stays in the water, complexes dissolved IBP, raises both solubilities and charges the droplets to about +65 mV; its fresh droplets are larger, 472–808 nm. R1·R11·R6·R5 Over 3 h of stirring, HPMC and EUD-E kept about 70% of the droplet-phase drug dispersed, PVP-VA about a quarter, and without polymer the droplets creamed within an hour. R15 The authors' conclusion is that polymer mixing with the drug-rich phase trades a lower maximum supersaturation for better size stability, and that steric (HPMC) or charge (EUD-E) repulsion decides whether the droplets last; the ripening and steric-repulsion steps remain interpretations. C52·C47·C49·C51·X2·X3